The Drug Discovery World Podcast DDW Highlights: 23 December 2024
Dec 23, 2024
Recent funding initiatives are making waves in drug discovery, with $300 million secured by an AI-driven firm and Ottimo Pharma's impressive financing. Collaborations, including Tessera Therapeutics and the Gates Foundation, aim to tackle fibrosis and sickle cell disease. Genetic medicine is advancing with breakthroughs for sickle cell treatment and a new bifunctional antibody in cancer therapy. The role of AI in research continues to expand, enhancing capabilities and igniting innovation across the industry.
AI Snips
Chapters
Transcript
Episode notes
New Fibrosis Therapeutics Company
- Venture Studios, Deep Science Ventures, and General Inception will create a company for novel fibrosis treatments.
- They aim to overcome current bottlenecks in fibrosis therapeutics.
Cradle's AI-Powered Platform
- Cradle, an AI-powered protein engineering platform, raised $73 million in Series B funding.
- A biotech customer used Cradle to accelerate a P450 enzyme's activity four-fold in three rounds, compared to ten previously.
Sickle Cell Disease Treatment
- Tessera Therapeutics partnered with the Gates Foundation for a sickle cell disease (SCD) program.
- They aim to develop a one-time, in vivo curative treatment using GeneWriters.